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Summary 
Depo-medroxy Progesterone Acetate (DMPA) is a progesterone-only injectable 
contraceptive, that is provided in three-monthly doses. It has been approved by the 
Government of India for provision in the commercial sector in India, where it is 
marketed under the brand name Depo-Provera and can be procured on a doctor’s 
prescription. During 1996 it was available at rates that range between Rs. 140 to Rs. 
180 per injection. At this price, however it is often beyond the reach of many women 
wanting a safe and effective contraceptive. Because of the progesterone content, it 
is indicated for use by lactating women. Its side effects are related to initial 
disturbances in the menstrual cycle, from irregular spotting or bleeding to complete 
amenorrhoea. Fertility usually returns within nine months of last injection. 
In January 1996, DMPA was provided to women in three cities of Uttar Pradesh, 
specifically Agra, Lucknow, and Varanasi through Parivar Seva Sanstha’s (PSS) 
clinics at Rs 150. PSS is the Indian affiliate of Marie Stopes International. In July 
1996, as part of the operations research the price of DMPA was reduced in Agra to 
Rs. 50, in Varanasi to Rs. 0 and Lucknow to Rs. 100. with an initial clinical 
examination charge of Rs. 40 at all clinics Information was collected on these 
services and clients for a total of eighteen months, to understand how price 
influenced the demand, perceptions and use of  DMPA among urban women in Uttar 
Pradesh at different prices. The study seeks to better understand client perspectives 
on the product and its price, and in this context it should not be viewed as a 
traditional clinical trial. Since awareness about injectable contraceptives was very 
low in these cities, initial publicity about the method was undertaken. This was done 
at the three cities through fortnightly advertisements in the Sunday edition of local 
editions of Hindi newspapers as well as in three editions of two women’s interest 
magazines, wall paintings and billboards. 
The injectable was provided by PSS under conditions where the quality of counseling 
about side effects was standardized and could be monitored. Information and 
educational material on the range of contraceptive methods offered at the clinics were 
provided to all prospective clients, and additional material and a client appointment 
card was given to each woman accepting DMPA Clients were encouraged to return 
to the clinics for further counseling if needed and side effect follow-up was provided 
at no additional charge. No further effort was made for follow-up if a client did not 
return to the clinic. 
. 
In all a total of 662 women accepted at least one dose of DMPA during April 1996 
to September 1997. Sixty-four percent of the women had used a modern method of 
contraception earlier. The most commonly mentioned methods were condoms (64 
percent), IUD (33 percent) and pills (24 percent). After the price change, the increase 
in use of DMPA was highest at Varanasi. and lowest at Lucknow. However the 
effect of the price change was not sustained oker time, as the clinics registered a 
decline in new acceptors after the initial rise 
The greatest barrier to first time use was lack of knowledge of anyone who had 
actually used DMPA, and a fear of possible side effects, especially amenorrhea or 
absence of menstrual periods. Fifty-four percent of the first injections were given 
to women following an MTP. In general DMPA represented 5-8 percent of the total 
family planning visits at the PSS clinics. 
Continuation of the product was low, with only 44 percent of users returning for a 
second dose, and 29 percent seeking a third dose. Only 19 percent of acceptors used 
DMPA through one year (4 doses). Continuation rates among clients improved 
significantly over the study period. More than half of the clients ( 55  percent) who 
received their first injection during the second half of the study returned for the 
second dose and 39 percent for the third dose. The median duration of use was about 
6 months. Among all users, many lapsed because of side effects, primarily 
amenorrhea, followed by irregular menstrual periods. Price was not mentioned as a 
reason for not taking the next injection. I% pregnancies were reported among users 
of DMPA during the study period. A follow-up of 114 women who had stopped 
using the method, indicates that the most commonly mentioned contraceptive 
methods used following discontinuing of IIMI’A were condoms (26 percent), orals 
(18 percent), IUD (7 percent) and tubectomy (7 percent). About 40 percent stated 
that they were not using any method. 
From a management perspective, the most significant factor for PSS in sustaining the 
sale of this product was the wholesale price, i.e. Rs. 95 when the study began and 
currently about Rs. 120. A cost analysis identified wholesale price as the most 
critical issue for PSS. Per 100 clients, Lucknow would be the only clinic to have a 
positive income from DMPA services at the current price to clients (Rs. loo), if 
advertising costs were not included. All other clinics provided DMPA at a loss, 
given the high wholesale cost of the commodity. All other associated service costs, 
with the exception of advertising, were relatively modest. Estimates suggest that Rs. 
35 would be an affordable wholesale cost for PSS, compatible with the current 
pricing sti-ategy in both Lucknow and Agra. If supplies could be obtained at below 
Rs. 35, then obviously net income would incrcase, other things being equal. 
In conclusion, DMPA appears to be an acceptable, safe method of contraception 
when offered in a context of good client counseling and follow-up. By providing 
DMPA, PSS offered a broader contraceptive choice to their clients. More effective 
public information about the method and its availability would greatly improve its 
access. Ensuring the availability of the product at an affordable wholesale price in 
India would both meet the needs of potential clients as well as facilitate the financial 
sustainability of the service by PSS. 
I. Introduction 
A. Background 
Depo-medroxy Progesterone Acetate (DMPA) is a progesterone-only injectable, that 
is provided in three-monthly doses. About I2 million couples throughout the world 
now use DMPA and other injectable contraceptives, approximately 3 percent of 
contraceptive users. DMPA is approved for use in 106 countries. Table 1 provides 
contraceptive prevalence data by method for selected countries the region (WHO, 
1994). Examining the proportion of modern method use represented by DMPA, 
injectables account for about 14 percent of users in Bangladesh, 29 percent in 
Indonesia, 8 percent in Nepal, 11 percent in Pakistan, 7 percent in Sri Lanka and 17 
percent in Thailand. Data on contraceptive method use in India from the National 
Family Health Survey (IIPS, 1993) and from sample surveys in selected districts of 
Uttar Pradesh (BSUP, 1996) show clearly that injectable contraceptive use is 
negligible, less than one percent of family planning users. To date, injectable 
contraceptives are still not provided within the Indian family welfare programme. 
In contrast, injectables have been part of the Bangladesh family welfare programme 
since 1976. 
. 








Source: WHO, 1994 



































Under the brand name Depo-Provera, the three month injectable (DMPA) produced 
by Pharmacia & Upjohn has been approved since 1993 by the Drug Controller of 
India. It is licensed for distribution in the commercial sector on prescription by 
private physicians. A two-monthly injectable. NET-EN produced by Shering AG, 
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is also marketed through private physicians. The products and the duration of their 
effect are indeed different, but the medium of administration is the same. Injections 
of DMPA can be administered by paramedical or medical staff, and are given in the 
muscle of the arm or buttock. 
Injectable contraceptives combine high levels of effectiveness with reliable 
reversibility (Population Reports, 1 987). Moreover, as a progestin-only product, 
DMPA does not have an adverse effect on lactation, an important feature in India 
where lactation commonly extends to more than one year postpartum. Most trials 
report less than one percent method failure, niaking injectables comparable with most 
clinical methods. In terms of reversibility. a study conducted by the Indian Institute 
for Medical Research (ICMR) study found that 69 former injectable users (NET-EN) 
conceived on average of 1 1 months after their last injection (ICMR, 1990). 
The ICMR study also reported that dirruption of regular menstrual bleeding and 
amenorrhoea are the most cominon side effects of the progesterone-only injectables 
(NET-EN) and the main reason women stop using them (ICMR, 1990). Counselling 
on these side effects is an important element of service delivery and a major 
determinant of satisfaction and continuation. In Ecuador, DMPA users in private 
clinics actually experienced slightly fewer side effects, and fewer accidental 
pregnancies than pill users (Foreit, 1995). Certain groups do have different 
experiences with the product. For example. in Turkey a study reported that the 
continuation rate for postabortion clients for the first year of DMPA use (47 percent) 
was lower than that for interval and postpartum users (Pile, 1998). Philippines data 
suggests that spousal support is also impor-tan t for continuation (Costello, 1995). 
The precise annual cost for methods provided through the public sector in India is 
difficult to determine. However, IJNFI'A cstiinates the comparable cost per couple 
year of protection (CYP) for methods provided by the public sector in India to be 
US$0.50 for sterilization, US$0.80 for the IIJI), US$2.30 for pills and US$4.00 for 
condom (INFPA, 1993). The private sector also supplies all these methods at 
market and subsidized prices through private physicians as well as commercial and 
social marketing programs. Physicians seem quite interested in injectables. For 
example. a recent Indian Medical Association (IMA) training evaluation suggested 
that IMA affiliated physicians were interested in learning about DMPA. and their 
knowledge about the method increased signifit antly during training (CORT, 1995). 
However, DMPA and Net-EN are methods that are not available in the public sector 
and are only available at commercial prices through chemists and private physicians. 
Product price is one of the major factors affecting access, adoption and continuation. 
A review of 15 experimental progranis suggests that charging a tnodest fee for 
contraceptive services and products (rather than providing them free) does not have 
a negative effect on demand. Price reductions c onsistently, however, led to increases 
in demand. Furthermore, efforts designed to recover the full costs often deter low- 
income and moderate income clients from seeking the service (Lewis, 1986). 
Similarly high prices dampen sales and tend to shift users to other sources or less 
expensive methods (Lewis, 1992). For example, in 1990 Bangladesh increased 
prices in their social marketing program by about 60 percent in the hope of 
recovering more costs, and as a result sales of orals dropped by 12 percent and 
condoms by 29 percent (Ciszewski and Harveq, 1995). 
Distribution of DMPA in India is currently being conducted through the commercial 
sector to private physicians. The prices mentioned by women who bought DMPA in 
Lucknow in April 1995 was Rs. 140 to Rs. 1 80. DMPA can be obtained wholesale 
through large pharmacies with clinic discounts ior about Rs. 1 I0 to 124. Pharmacia 
& Upjohn report that the slow pace of marketing of the product has been deliberate, 
given the interest in quality and the upscale market segment which has been targeted. 
But sales have been modest. For example, a Retail Store Audit conducted monthly 
throughout the country shows that in Uttar Pradesh no more than 600 vials were sold 
per quarter since April 1996 (ORG, 1997). 
A post-marketing surveillance study sponsored by Pharmacia & Upjohn is underway 
nationally with 10 reporting sites to identify potential clinical problems associated 
with longer term DMPA use, as well as look at issues of acceptability in the private 
sector. Parivar Seva Sanstha (PSS), the Marie Stopes Affiliate in India, participated 
in this post-marketing surveillance study. The clinical experience of PSS with 
DMPA users suggests that the dynamics of DMPA use in India in terms of client 
concerns, effectiveness and side effects is similar to that reported in the international 
literature (Population Reports, 1987). ‘The interest of PSS in expanding the 
contraceptive options available for women forms that backdrop for this study on 
clients’ choices and product price. 
B. Objectives 
The following were the principal objectives of the operations research: 
To broaden the choice of affordable contraceptive methods available to PSS 
clients. 
w To examine the differences in demand, client profile and satisfaction with DMPA 
at three prices to clients. This would lead to policy recommendations on the use 
of the method in different cost settings within PSS. 
w Contribute additional data to the policy debate on the role of injectables in India. 
The study hypothesized that reductions in the price of DMPA increases contraceptive 
choice. The study aimed to assess which price most closely met the clients' 
perceptions of an affordable, good quality. contraceptive service, and at the same 
time ensured the financial sustainability of' the service from the provider's 
perspective. 
11. Research Methods 
A. Design 
A mix of qualitative and quantitative research methods were used to assess client 
demand and satisfaction with the product in three Parivar Seva Sanstha (PSS) clinics 
in Uttar Pradesh at three price levels, all currently below the prevailing PSS price of 
Rs. 150. Three PSS clinics in Varanasi, Agra and Lucknow were assigned a different 
price to be charged to clients for DMPA. The prices of DMPA in the three settings 
were as follows: Rs.0 in Varanasi, Rs. 50 in .4gra and Rs. 100 in Lucknow. With the 
high wholesale cost of DMPA supplies (Rs. 95). the service was heavily subsidised 
at the first price, modestly subsidized at the second price, and available at about the 
wholesale price in the private sector in India at the third price. At the time of initial 
acceptance, the clients were charged an additional gynaecological examination charge 
of Rs. 40 at all clinics. Communication materials to support client counselling were 
developed and distributed at the clinics. All follow-up services related to side effects 
were free. 
The research design is illustrated below: 
Varanasi Clinic (Rs. 0) 01 x 0 2  X + A  0 3  
Agra Clinic (Rs. 50) 0 1  x1 0 2  Xl+A 0 3  
Lucknow Clinic (Rs. 100) 0 1  x2. 0 2  X2+A 0 3  
01= 
0 2 =  
0 3 =  
X =  
xl= 
x2= 
A =  
Observations on client characteristics and demand prior to the price change. 
Observations on client characteristics and demand following price change. 
Continuation and follow-up of users, and estimation of the effect of 
advertising. 
DMPA provided at Rs. 0 plus examination charge of Rs 40 and no charge for 
subsequent injections. 
Product provided at Rs. 50 for first and subsequent injections with Rs. 40 
examination charge. 
Project provided for Rs. 100 for first and subsequent injections plus Rs 40 for 
examination charge at first injection. 
Advertising 
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The study seeks to better understand client perspectives on the product and its price, 
and in this context it should not be viewed as a traditional clinical trial. To protect 
the confidentiality of client identity, no attempt was made to follow-up on all clients 
who accepted DMPA. 
Advertising the Availability of DMPA 
As DMPA is a relatively little known product in India, the design also included an 
embedded test of the impact of low level advertising on the demand for the service. 
In all three cities, advertising of the availability of DMPA was conducted by PSS 
through local print media, specifically Hindi newspapers and magazines, and the use 
of billboards and wall paintings in neighbourhoods served by PSS. The content and 
layout of the adverstisments were based on suggestions from focus group 
discussions, and proofs were pretested with potential clients prior to publication. 
The advertising consisted of 24 advertisements, each about 14 square cm., which 
were published fortnightly in the Sunday edition of two leading Hindi newspapers in 
each city. The newspapers included: Amar LJjala, Dainik Jaggran, Rashtriya Sahara 
and Aaj . The articles and ads in women's magazines were placed in Sarita and Griha 
Shobha. The ads provided limited information about the availability of the DMPA 
service and specified the price charged at the nearest PSS clinic. The advertisments 
were published from October 1997 to March 1998. 
Simultaneously PSS contracted for one bill board and several wall paintings in 
strategic locations to inform potential clients about the new product. Agra also 
contracted about 10 kiosks on a bus) street to advertise the service. Copies of 
orientation materials on DMPA and its charxteristics w7ere also sent to a local 
mailing list of private physicians for their information and referral. 
B. Parivar Seva Sanstha (PSS) and Collaborators 
PSS is a non-profit society registered in 1978, under the Societies Registration Act 
of 1860. It is affiliated with Marie Stopes International, and manages 30 
reproductive health clinics throughout India. PSS has reproductive health service 
projects in the New Delhi, and the states of Uttar Pradesh, Haryana, Rajasthan, 
Madya Pradesh, Himachal Pradesh, West Bengal, Tamil Nadu and Karnataka among 
others. Its donors include DFID, SOMARC, SIFPSA, European Union, the 
Population Foundation of India and USAID. It not only operates reproductive health 
clinics, but also is involved in reproductive health training and education, social 
marketing, community based distribution ol'coiitraceptives, family life education and 
orientation for adolescents. 
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It has 30 clinics and 3 outreach projects, and is an affiliate of Marie Stopes 
International, London and its clinics are sometimes called “Marie Stopes Clinics”. 
PSS had introduced DMPA as a contraceptive choice in a few selected clinics in 
August 1994 at Rs. 150, along with a gynaecological check-up charge of Rs 40-50. 
From January 1996 it was offered in all 30 clinics. In one of PSS’s outreach projects 
in Mewat, Haryana, DMPA was also made abailable through home visits at Rs. 20 
per dose with high levels of acceptance. 
As implementing agency, PSS was responsible for identification of the sites, specific 
pricing strategies, staff arrangements and overall management for the project. PSS 
also identified a source for supply of DMPA, and was responsible for the purshase 
of supplies. MaxPharma, the Indian company contracted by Pharmacia & Upjohn 
to supply DMPA to the national market, stopped its supply in January 1997. 
Thereafter. Pharmacia & Upjohn assumed direct responsibility for supply and 
distribution of DMPA. During the short period when commercial market supplies 
were not available, PSS clinics did not face any shortage of DMPA as in-house 
stocks were sufficient. 
The Population Council provided technical assistance to PSS on the overall injectable 
strategy, in the conduct of the research, including data analysis, and in the preparation 
of reports. Direct observations of counseling and care were made, and interviews 
with providers and clients were conducted during routine visits by Council staff to 
the service sites. Data collection from DMPA client intake forms was the 
responsibility of the PSS physicians at the clinics, with the supervision and support 
of the project director. Media and message components of advertising were done by 
PSS in collaboration with IMAGINE. an advertising and communications firm in 
New Delhi. The qualitative follow-up research to analyse the perceptions of non- 
users, lapsed users and current users was conducted by the New Delhi based social 
marketing group, ADMAR Private Services Limited. 
C. Site Selection 
The present study took place in the three largest PSS clinics in Uttar Pradesh (e.g. 
Agra, Varanasi, Lucknow). All clinics provide a wide range of family planning and 
gynaecological services, and DMPA is simply mentioned during counselling as one 
of the options available. At least one wall chart in each clinic identifies the methods 
available. Public sector contraceptives, e.g. condoms and orals, are provided free of 
charge, while social marketing products are charged at the following rates: four Bliss 
or Sawan condoms for Rs. 2, and one cycle of Ecroz for Rs. 6. There is no charge 
for a copper IUD T200A, although a gynaecological exam is charged at Rs. 40. Both 
female and male sterilization services are provided free, and the government 
sanctioned user fee is paid to clients to cover. their expenses, Rs. 145. Medical 
Termination of Pregnancy (MTP) services are offered as well, and are charged on a 
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sliding rate depending on the number of weeks ofpregnancy, e.g. 6-8 weeks, Rs. 375 
or Rs. 475 for 10-12 weeks. 
The Lucknow clinic is located in the state capital, with an urban female population 
of reproductive age of approximately 363,000. The PSS clinic is in a rented facility, 
with the clinic on the first floor. It has been in the same location, a side street off a 
major thoroughfare, for about four years. This clinic is staffed by two women 
physicians, all who provide client screening, counselling and injectables. Prior to the 
study (since August 1994), the clinic had been providing DMPA to a total of about 
190 clients. About half of the DMPA clients received the first injection post-MTP. 
Monthly provision of injections ranges from 10 to 22 clients, with about half being 
first injections. A small number of clients have continued for one year, but two 
injections is the most common duration of use in each clinic. The providers suggest 
that the principal reasons for drop out are the high cost of the product, amenorrhoea 
and spotting. During January 1996, PSS sened 475 clients. About one-third of the 
clients seek an MTP. and about half are intercsted in other women’s health services. 
I 
The Agra clinic is located in the large industrial and tourist city, with an urban 
population of about 23 1,000 women of reproductive age. The clinic is also in a 
rented house; it has limited space but operates very efficiently. It has provided 
DMPA since December, 1995, and reported I 1 IIMPA users prior the study. Most 
clients are poor and many come from rural areas as far as 40 kilometres from Agra 
for clinical services. The medical staff is composed of one-full time and two part- 
time women physicians. all with Ob/Gyn degrees or diploma training. Like in the 
Lucknow clinic, they are largely responsihle filr screening, counselling and providing 
injections. Counselling is done in a small partitioned counselling room. During 
January 1996, the clinic served 935 clients of which 312 attended the clinic for 
MTP . 
The Varanasi clinic is located near the train station on a busy road in this traditionally 
religious Hindu city, with an urban population of about 276,000 women of 
reproductive age. The clinic has been in the same location for the last eight years, but 
Marie Stopes has offered clinical services in Varanasi for over 12 years. The clinic 
is staff by two full-time women physicians. two nurses, one clinic attendant, one 
operating theatre attendant, and one manager/counsellor. DMPA has been provided 
in the clinic since December 1994, and served a iota1 of 22 users of injections prior 
to the study. Most have used only one dose, and none has used more than two doses. 
As in the other clinics, price and amenorrhoea are the principal stumbling blocks for 
greater acceptance. During December 1905, the I’SS clinic served about 375 clients, 
of which 204 attended PSS for an MTP. 
All three clinics are located in accessible inner city areas, are well marked, and have 
attractive facilities relative to the local market They offer basic laboratory facilities 
for identifying blood type, and conducting haemoglobin and urine tests. They 
provide pap smears on request, but the slides are sent to a referral clinical laboratory. 
PSS also cooperates with the public sector in major campaigns, such as the recently 
completed Pulse Polio immunization drive and adolescent girls' Iron 
Supplementation campaign. 
All clinics maintain records of demographic and medical profiles of clients, including 
data on age, profession, income, education, menstrual history, obstetric and 
contraceptive history, lactation, the result of medical examination, and the schedule 
for follow-up visits to the clinic for each client. It is PSS policy to limit follow-up of 
clients in the community to protect their confidentiality. In addition, the clinics keep 
a simple DMPA users register, with information on name, age: parity, address, and 
dates of injections, as well as remarks. A pregnancy test was available to DMPA 
users, who were concerned about amenorrhoea. Clinical examinations and menstrual 
history were more commonly used to rule out pregnancy at the first visit. 
D. Subjects and Informed Consent 
All clients at PSS are offered the range of contraceptive methods available at PSS, 
including IUDs, orals, condoms, sterilization and DMPA. All clients are provided 
counseling and have access to IEC materials. Selection of the particular method is 
voluntary and based on informed consent. All women for whom DMPA was not 
contraindicated and who chose the method were eligible for the study. All clients 
were counselled about side effects and, i f  accepting DMPA and willing to be 
followed-up at home, were asked to sign a consent form. All clients were assured of 
the confidentiality of the information they provided. The identity of users was only 
available to the clinicians and the research team. Client records were maintained in 
a locked cabinet. Clients were assured that they could discontinue use of DMPA or 
drop out of the study for any reasons, without consequences. 
E. Data Collection 
Table 2 provides a list of the source of information used for individual data variables. 
Data collection took place over a period of 18 months, and also included: 
The number of DMPA vials and syringes in stock were routinely monitored. This 
information was maintained by the clinic manager and reviewed at the PSS 
central office and at the time of visits by PSS and Council staff. Standards for 
safety and disposal procedures for DMPA materials were reviewed in July 1996, 
and checked periodically during clinic site visits. 
Information on counselling and quality of care was collected by direct 
observation at all three clinics by Population Council staff and interviews with 
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providers. Quarterly meetings were held to assist in problem solving and sharing 
analysis with clinic staff. 
1 F I  Data Collection 
Methodology Interviewed 
An analysis of the cost to PSS of providing DMPA in each of the three sites was 
conducted by the Population Council in January 1997. 
Information Collected 
ORG Retail Shelf 
Audits. 
Structured Client 








Total value and volume of DMPA 
sold through commercial channels. 
Demographic and economic profile 
of uxrs .  Reasons for selecting 
DMPA. Prior contraceptive use and 
reasons tor accepting contraception. 
Group Discussions 
(GDs) with women 
not using DMPA in 3 
cities. 
In-depth interviews 
with women who 
discontinued DMPA 
use. 








Perceptions of awareness and use of 
FP methods, and specifically 
perceptions of DMPA. 
Perceptions of DMPA, level of 
satisfaction and reascns for 
discontinuing method. Sensitivity 
to price change. 
In-depth interviews 
with women who are 
currently using 
DMPA. 
Clielit cards on FP use 




6 1 -Varanasi 
30 PSS 
clinics 
Perceptions and use of DMPA, side- 
effects and their management. 
Purchase intc.nt at different prices. 
Relative provision of different 
family planning methods. 
Variables II 





data on clients. 
What is the general 
awareness of DMPA 
among potential users. 
Reasons for discontinuing 
DMPA. Other FP method 1 currently used. 
Reasons for continuing 
DMPA. Other issues 
related to price. 
Method mix in all PSS 
clinics. 
F. Research Management 
Table 3 highlights the major activities and their placement in the time line from April 
1996 to September 1997. The major events included the training of staff and the 
development of IEC materials on CMPA for clients and providers, focus group 
discussion with clients, the management of price changes, development of an 
advertising strategy and campaign, the cost analysis and the follow-up study. 
To assist in the coordination of these actjvities at the clinic level, quarterly meetings 
were held with PSS New Delhi staff, clinic managers and doctors. Meetings were 
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organized by Dr. Sneh Vishwanath, the principal investigator from PSS, New Delhi 
with Drs. Leila Caleb-Varkey and John Townsend of the Population Council. 
Review meetings were held in April 1996 in New Delhi, October 1996 in Agra, 
February 1997 in Lucknow and July 1997 in Varanasi. 
Table 3 Study Time Line by Quarter Apr 1996 to Sep 1997 
In June-July 1996, field visits were made to each of the clinics for standardization of 
the protocol and procedures for client screening, counseling, management of side 
effects, disposal of waste material, data recording arid reporting and pilot testing the 
newspaper advertisements. Throughout the study, staff from the Population Council, 
USAID and PSS headquarters visited each of’the sites to make direct observations 
and to see that standardized procedures were being followed. Given that PSS is a 
service rather than a research organization, lhe volume of data collected and 
scheduling of interventions was well managed. PSS also learned a great deal about 
the management of operations research and timely utilization of emerging 
information during the process. 
111. Results 
DMPA Dose 
First Dose (clients) 
Percent of Acceptors YO 
A. Number of Clients 
1 - G T l - n -  
662 298 I99 165 
45 30 2s 
The study was designed to examine the effect of DMPA price at three PSS clinics on 
the number of clients using injectables and the number of doses provided over time. 
Table 4 describes the total number of clients and DMPA doses provided during the 
study. In absolute terms, price clearly made a difference in the total numbers of 
clients and DMPA injections given within the same period of time at the three 
clinics. In Varanasi, where DMPA was available at no charge, there were a total of 
298 DMPA clients and 473 doses given; at Agra (Rs 50) there were 199 clients and 
a total of 324 doses administered; and at the highest price Rs 100 in Lucknow, there 
were 165 women served and a total of 297 doses administered between April 1996 
and September 1997. 
In terms of total doses provided, the volume of DMPA use in these clinics is 
relatively modest. Less than 1 100 doses were provided during the I 8 month study 
period. However, information from all thirty PSS clinics in the country indicate that 
a total of 2849 injections of DMPA were provided in the year July 1996 to June 
1997. Of these, about 33 percent were provided in the three study clinics in Agra, 
Lucknow and Varanasi alone. 
The data in Figure 1 show the number of first doses provided over time at each of the 
clinics. Note that not all the clinics began at the same level, e.g. the number of users 
in Agra had already increased to nearly 50 during April-June 1996 from a pre-project 
number of less than 15. It is evident from the figure that following the price change, 
there was an increment in first time use in all three clinics. In Varanasi and Agra, the. 
number of new acceptors decreased slowly thereafter, even during the period of 
advertising from October 1996 to March 1997. In L,ucknow, at the highest price, first 
time users peaked during the semester when the advertising occurred and only 
thereafter declined. 
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Figure 1. New DMPA Acceptors Over the Study Period 
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Table 5. DMPA Acceptors at the Three Clinics Apr 1996 to Sep 1997 
July 1,  1996 
Jul96-Sep 96 
3 months 
Oct 96-Mar 97 
6 months 
Apr 97-Sep 97 
6 months 
Apr 96-Sep 97 
1 4 8  114  
8 
Rs. 0+40 Rs. 50+40 Rs. 100 
As can be seen from Table 5 ,  with the exception of Agra, the largest increase in total 
users occurred during the period from October 96 to March 1996 when advertising 
was being conducted. While the monthly differences are not dramatic they are 
consistent with the hypothesized relationship to price. As advertising through the 
print media was discontinued in April 1997, the number of new acceptors diminished 
in all three sites. 
Relative Use of DMPA 
The distribution of family planning users b j  method at the three clinics is given in 
Table 6 below. At the three PSS sites, DMPA represented approximately 14 percent 
of all female contraceptive acceptors annually It also accounted for about 5-8 
percent ofthe family planning clinic visits to PSS. 
* Acccptors I> detincd as thc number ofcqclcs oforal\ pro: rtlec’ divided by 13 
The most popular method provided by PSS was pills, which were distributed through 
both the clinic and outreach services. Tubectoniy was the second most common 
method, followed by the IUD. There were signillcant differences in terms of method 
use by site, with tubectomy the most common in Agra and orals the most common 
in Lucknow. When the study began, it appeared as if DMPA sales were partially 
replacing the sale of orals. However, as the study progressed, there was only a 
modest change in the oLeral1 method mix. 
Figure 2 provides an illustration of the trends in method acceptance for all 30 PSS 
clinics nationally over the time period of the study. Since January 1995, there has 
been a notable seasonal pattern in the number of IUDs inserted (1500 to 2300 per 
quarter) and sterilizations conducted (from 3500 to 7000 per quarter). The greatest 
number of cases occurs in the first quarter of each year aiid in the fourth quarter. 
This is the winter in India. and a traditional time lor adopting clinical methods. In 
contrast, there has been 21 gradual increase i l l  the nuiiiber of DMPA acceptors through 
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the first quarter of 1997, followed by a gradual reduction. At the same time that 
DMPA use slowed, there was a large absolute increase in the number of cycles of 
orals distributed nationally, an increase of almost 300 percent. For all PSS clinics, 
the number of DMPA acceptors represents about 14 percent of the total number of 
sterilizations, and 36 percent of the number 01’ TI1 D acceptors during 1997. 
Figure 2. Method Mix at PSS Clinics Nationally 
. 
ALL INDIA PSS FAMILY PLANNING ACCEPTANCE 
~~ ~- ~ ~ ~ ~ ~ ~ _ _ _ _  -~ ~ ~~~~ ~ ~ ~~ 
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Data from shelf audits conducted by ORG during the study period illustrated little 
commercial sale of DMPA in the state. For example, data on the total number of 
vials sold by commercial outlets in Uttar Pradesh from April to September, 1997 
show that only 600 vials were distributed, 100 were sold and 500 were still in stock 
at the outlets (ORG, 1997). Thus, commercial sales of DMPA in UP are still very 
low. The DMPA used for the present study was supplied directly by the PSS office 
in New Delhi and is not reflected in the shelf audits. 
B. Characteristics of Clients 
Table 7 provides information on the general characteristics of acceptors. Virtually 
all users stated that they were married. The median age of acceptors is about 27 
years, although clients ranged in age from about 18 to about 40 years of age. In 
terms of religion, they reflected the profile of the communities in Uttar Pradesh in 
which they live. Most were Hindu, but about 13 percent were Muslim, Sikh, 
Christian or other. Given the urban nature 01’ the clinics, women’s education was 
quite high with about 85 percent having some education, and 42 percent more than 











Data from the client record suggests that nearly half come from homes with a 
monthly family income greater than Rs. 3000 (about US$S5). The women tended to 
be better educated, and have on average a smaller family size than the general 
population of Uttar Pradesh. Women selecting DMPA were relatively similar across 
the three clinics. Yet, DMPA users in L U C ~ O W  were somewhat more educated and 
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Total N I 662 
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Reproductive and Contraceptive History 
Table 8 provides information on the clients' reproductive and family planning 
history. On average acceptors of DMPA had been married about 8 years and had 
about 2.5 children. Often the differences between clinics were considerable, e.g. an 
average of 1.9 live births among acceptors i n  I ucknow compared to 2.7 live births 
in Varanasi. It is noteworthy that 12 percent of users in Lucknow had not yet had 
children. On average, women had esperiencml their last child birth two years 
previously, with about 36 percent of users giving birth during the past twelve months. 
As a result, 44 percent of the women were breastfeeding at the time of first DMPA 
acceptance. This is important as DMPA contains only progesterone, does not 
interfere with lactation, and is preferred o\ cr combined oral pills for breastfeeding 
women. Progesterone only pills are not available in India. The use of DMPA among 
young, low parity women is an important featun: of the service from a demographic 
as well as reproductive health perspective. 
Data from the client cards indicates that almc>st all the clients (94 percent) were 
aware of some method of Lmily planning, p;irticularly sterilization. Ninety-five 
percent ot' the clients were aware of the availatlility of family planning services as 
well as Medical Termination of Pregnancy (MTP) services at PSS clinics. The level 
of awareness was almost identical in all three c!inics. Among spacing methods the 
highest level of awareness was of condoms (89 percent). 88 percent were aware of 
the pill and 86 percent were aware of the I (  L). 
The majority of women accepting DMPA had used another method of contraception 
previously. iiicluding 3 percent with earlier !experience with DMPA. For 5 percent 
of new acceptors DMPA was the first contraceptive method they ever used. About 
64 percent had used condoms at some time. 33 pcrcent the IUD and 24 percent the 
oral pill. Two percent of users in Lucknow had undergone unsuccessful tubectomies. 
About half of the women had discontinued !hi: previous method for a variety of 
reasons, :ncluding method failure and fm iil! concerns. About one-fourth had 
terminated the method due to unacceptablc \ t c k  effects. The differences between 
clinics were notable. For cxaniple, 85 tierc . s i l t  of women in Agra reported having 
used the condom compared I:-# only 40 pcrc:' I I I l'aranasi and 23 percent of women 
in Lucknow stated having used some traditiLliiLiI method compared to only 1 percent 
in Agra. 
Approximately 35 percent of the women said that they were using DMPA as a 
method for spacing births. while 65 percent stated that they did not want any more 
children but were not yet ready for sterilizatioi . Of clients accepting DMPA as a 
spacing method, 13 percent wanted a gap ot'fiv: years before conceiving again. 
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Table 8 Rem-oductive and Familv Plannin History 
1 
Variables YO Total 9’0 Varanasi YO Agra YO Lucknow YO 
~ ~~~ ~~ ~ 
Age at Marriage - median 
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13-24 months 
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44 45 42 31 Currently breastfeeding 
3urce: Client Cards 
Sources of Information about DMPA 
According to the client intake card, which was completed by the clinic counselor, 
about 20 percent of DMPA acceptors were previously aware of injectable 
contraception prior to visiting the PSS clinic. The most commonly mentioned source 
of awareness for DMPA was the doctor in the PSS clinics (37 percent), followed by 
the media (33 perccnt) and then the client’s husband and friends (14 percent each), 
although many mentioned multiple sources. Awareness was much greater in 
Lucknow (33 percent) and Agra (25 percent) than in Varanasi (7 percent). As DMPA 
is a relatively new method in India, health providers are important sources of 
awareness and their advice is relied upon b!, clients since women do not know others 
who use DMPA. 
Given the historical controversy surrounding injectables in India, it is noteworthy 
that there was no adverse reaction from public authorities, women’s health groups 
1 7  
or clients to advertising on DMPA which appeared in Sunday newspapers and 
women’s magazines over several months. Given the low key flavor of the campaign, 
it was seen as informational rather than promotional, and contained factual 
information available in the IEC materials. Public health authorities and the media 
had been briefed prior to the planned campaign by the local clinics. 
- 
Apr 96 - Srp 96 75 
Use of DMPA Post-MTP 
62 87 74 
Marie Stopes clinics provide safe and legal Medical Termination of Pregnancy 
(MTP) services, in addition to family planning and other reproductive health 
services. Women may seek care at PSS either for an MTP or care following an unsafe 
abortion occurring in another setting. All women seeking either an MTP or 
postabortion care are counseled and are encouraged to accept a reliable form of 
contraception following the procedure. Acceptance of contraception is voluntary and 
not a requirement for receiving any service. DMPA is an acceptable post-MTP 
method as it provides adequate contraception within 8 hours of injection. Its use also 
allows women time to discuss and accept longer term contraception with their 
partners and families as desired. 
~~~~ ~ ~ 
Oct 96 - Mar 97 
Apr 97- Sep 97 
Total (7 missing cases) 
~ 
56 45 78 57 
26 8 62 28 
54 37 79 56 
Table 9 presents information on the proportion of first time users who accepted 
DMPA after an MTP at all three sites. During the study period, 10,805 MTPs were 
carried out in the three clinics. Of these clients, about 3 percent (323) accepted 
DMPA. Over the study period. 54 percent of first time users of DMPA had just 
received an MTP. The differences between clinics is remarkable with 37 percent of 
DMPA using accepting post-MTP in Varanasi compared to 79 percent in Agra. 
However, there was no part of the training or clinical guidelines in any site that 
strongly recommended or emphasized use of DMPA at this particular time. 
Discussions with providers suggest that gik en the high volume of MTP users at these 
clinics, the pool of potential acceptors among this group was high. In all clinics 
however, the percent of reporting DMPA acceptance post-MTP declined over the 
period, as users began requesting the method as a routine family planning method. 
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Analysis of the characteristics of post-MTP users indicates no statistically significant 
differences between acceptors post-MTP and other DMPA users. 
Amenorrhoea 
Scanty periods and spotting 
Experience with Side Effects 
3 5 36 
34 22 
The potential side effects of any method are a concern to providers and users alike, 
and are an essential area of discussion during counseling. The experience with side- 
effects among acceptors in Uttar Pradesh was very similar to those found in previous 
studies involving DMPA. Of the 261 women who returned to the clinic for a first 
follow-up visit, about one-third reported no side effects. About another third (35 
percent) of acceptors reported amenorrhoea, and 24 percent had irregular spotting and 
scanty menstrual discharge. Excessive menstrual discharge was reported by just 3 
percent. DMPA acceptors were not asked to return to the clinic prior to their next 
scheduled injection, unless they had a particular concern or experienced side effects. 
One case of post-coital bleeding was identified as a suspected case of RTI. The 
pattern was similar for the second and subsequent visits, although the number of 
DMPA users who returned for a third and fourth check-up was only 53 and 20 
respectively. 
Excessive menstrual discharge 
Others, e.g. weight gain 
Table 10 Side-effects among Women who Returned for Follow-up Visit 
at First Follow-up YO at Second Visit 
No Side effects I 34 I 32 
3 7 
1 3 
The management of side effects was standardized through clinical guidelines in the 
three clinics. Following consultation with a physician, women with amenorrhoea or 
spotting were counseled and reassured about the nature of these side effects. A cycle 
of combined oral contraceptives was prescribed for women who reported 
menorrhagia, excessive menstrual discharge. Only 8 percent definitely stated that 
they were not willing to take the next DMPA injection because of' side effects. 
However, clinic data is not available on women who did not return for follow-up. 
Those returning may have done so either because of their interest in continuing 
DMPA use, or because they perceived the side effects severe enough to require a 
consultation. The qualitative data from the follon-up of users also provides data on 




The analysis included all women who took their first injection after July 1, 1996 
when the price changed and it also took into account whether they could have had the 
next dose by September 30, 1997, the last day of the study. Table 11 provides the 
DMPA continuation rates at the three clinics. Of eligible clients (592), 44 percent 
continued with a second injection, 29 percent returned for the third injection, and 19 
percent received a fourth injection (12 months). The three month continuation rates 
at all three clinics were of comparable magnitude, with users in Varanasi having the 
lowest rate of continuation (4 1 percent), followed by Agra (47 percent) and Lucknow 
with the highest rate at 48 percent. 
Number Cumulative Proportion Continuing DMPA Use 
Entering the 
Interval Total Varanasi Agra Lucknow 
Table 11 Life Table Analysis of Use of DMPA Jul 1996 to Sep 1997 
All three clinics report median use of less than 0 months. There was no difference 
in continuation between those who received the method following an MTP and 
others. Nor was an association found between continuation and other variables such 
as reproductive intentions (spacing versus limiting), breastfeeding status, income, or 
education. No discontinuation of the method was recorded due to the failure of the 
method. There was only one case in which a mornan, who had discontinued DMPA 
due to amenorrhoea following the first injectron, returned eight months later 
pregnant. 
Continuation rates among clients improved significantly over the study period. 
More than half of the clients (55 percent) who received their first injection during the 
second half of the study returned for the second dose and 39 percent for the third 
dose. The median duration of use during the second half of the study was 6.3 
months, compared to 5.3 during the first half of the study. This suggests that 
procedures for client selection and counseling improved with experience. 
These continuation rates are lower than those commonly cited in the literature 
(Population Reports, 1987). For example. a multinational study conducted by WHO 
reported in 1982 that continuation rates for DMPA at 6 and 12 months were 68 
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percent and 49 percent respectively. Studies in Bangladesh, where DMPA was 
introduced in the public sector in 1976, commonly report continuation rates of 
around 50 percent at 12 months (Phillips, et a1 1990). The difference with the PSS 
experience may be a function ofthe lac]\ o f  twtreach for follow-up, the limitation of 
a single site for obtaining the service, or the characteristics of clients who use PSS 
clinics. All three factors have the potential t’or limiting continuation of a given 
product. 
C. Clients’ Perception of DMPA Experience 
The perceptions of potential clients and actual users of DMPA were probed through 
two qualitative substudies conducted as a follow-up. First, nine focus group 
discussions were carried out in the three cities with a total of about 80 women, aged 
2 1-45, who had never used DMPA. The stucij rcported their perceptions about fidmiiy 
planning methods in general. and their awaizness and perception of DMPA. Second, 
in order to understand womens’ perceptions $ ) f  DMPA, another qualitative study 
conducted in-depth interviews with 176 c urrcnt and 1 14 lapsed uszrs in all three 
cities. All subjects fhr follow-up werc se1ci.tt.d from the list of women consenting 
to be contacted at home from the PSS clin!cs. 
’ 
Awareness of DMPA among Non-Cisers 
For non-users of DMPA, the most important consideration in selecting a 
contraceptive method was “effective protcction from unwanted pregnancy”. The 
other considerations were freedom from ;id< effects, ease of use, acceptance by 
husband and stories of positive experienccs on  DMPA from friends. relatives and. 
most importantly other users. 
Oral pills, IUD, condoms and tubectoniy v, ere the most commonly known and used 
contraceptives across all three sites irrespective of age groups. Never users in all 
three cities were only vaguely aware 01‘ the availability of an injectable contraceptive 
in Uttar Pradesh. They lacked any informed avareness of the method; for example, 
when it could be used, how- frequently it had tc’. be used, its potential advantages and 
disadvantages and the cost per injection. Many thought that it required an 
examination and clinical tests before u s  Ilo\vever, when it was explained to them 
that DMPA was a three-monthly injecllon +hat works as a contraceptive, it was seen 
as a good alternative choice. 
The sources of information on DMPA mentioned by never users were the newspaper 
and magazines, radio and doctors. Some mentioned th.e specific newspaper or 
magazine they had seen the advertisvmeiit i l l .  As none of the women had tried 
DMPA, they did not have any knowledge of side effects. Their comments included 
the following: 
“Seen other ads but never seen this one ... hence did not try” 
“Never seen or heard anybody using it.. 7‘he ads don’t show any experienced lady 
talking. .new product ... injections ufter (ill.. was not sure ’’ 
When asked if they knew how much it cost, very few could mention the price. 
However, when asked how much they would be willing to pay for such a 
contraceptive, the price range of Rs. 50-100 every three months seemed reasonable 
provided it met with their expectations. Coninients included: 
“rfit costs Rs. 50, it is quite reasonuhle Pills might he cheaper but then it has a lot 
of botheration ulso ’’ 
“f l i t  i s  Rs 150 also I know it becornc.s costly hut I may still go.for it to become 
ten.sion,free. ” 
“Think about the cost of abortion ... its pain ... its bad effects on health ... its costs, 
consider the cost of bringing up a child today..I think it is worth even a little extra”. 
The major reasons for not trying DMPA were a lack of informed awareness of the 
product and lack of reassurance from current users. For a new coctraceptive method 
in India, word of mouth may be the best advertisement. Recall of the DMPA ads was 
low even after exposure. The absence of live role models (i.e. friends, relatives who 
had used DMPA and were satisfied) failed to create credibility for DMPA. 
Experience of Current and Lapsed Users of DMPA 
A total of 176 current users (CU) and 1 14 lapsed users (LU) were interviewed at their 
homes at least 6 months following their acceptance of the product. Analysis of the 
demographic and socio-economic profile of current and lapsed users showed that 
there were no significant differences between the two groups. Moreover, there were 
few differences between the continuing and lapsed users on awareness of the IUD, 
pills, condoms and other spacing methods 
According to Table 12, respondents in the follow-up mentioned that the most 
important sources of information on DMPA were husbands, fiends, relatives, clinic 
personnel and the family doctor. Word of mouth was the main source of information 
as advertising merely let people know i t  was a1,ailable. Recall of advertisements or 
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wall paintings was not high, especially among lapsed users. Exposure to the 
advertisements was not as salient as a live example. Respondents preferred to hear 
about DMPA from a satisfied user, rather than through advertisements. Only 35 
percent of current users (CU) and 25 percent of lapsed users (LU) had actually seen 
the advertisements. Of those who had seen the advertisements, 63 percent of CU 
and 75 percent of LU had seen them in the print media. and 34 percent of current 








HospitaliFP clinic 26 27 
Sisterhister-in-law 9 14 
Mother 5 5 
Total n= 176 n=l14 
Advertising 15 10 
Family doctor 3 2 
Knowledge about DMPA 









DMPA injections are given once in every 3 months. 
DMPA injections should be given only by doctors/nurses. 
DMPA injections lead to side effects like irregular periods. 
It is quite easy to conceive after discontinuing DMPA injections. 
The first DMPA injection has to be given within 5 d a y  of 
completion of last menstrual period. 
The first DMPA injection can also be given immediately after 
abortion. 
DMPA injections provide better protection than other 
contraceptives. 
The level of knowledge about DMPA among both current and lapsed users was high, 










DMPA injections do not protect against STD and AIDS I 48 I 44 1 
In general, this good level of knowledge is a reflection of the quality of the 
counseling provided by PSS, as alternative sources of correct knowledge about 
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DMPA are limited in Uttar Pradesh. The IEC materials for clients as well as 
providers contained all these messages. The fact that DMPA does not protect against 
STD/AIDS was reported by less than half of the clients, suggesting that this issue 
was less frequently included in client communication. 
Perceptions ot DMPA 
Perceived Advantages and Disadvantages of DMPA 
Current Users YO Lapsed Users % 
Women were asked about the perceived advantages and disadvantages of the method, 
regardless of their personal experience with the product. According to data in Table 
14, protection against pregnancy was the single most important perceived advantage 
of DMPA, even among those who had stopped using it. Its longer duration of 
effectiveness makes it more attractive than methods which must be used daily, or in 
conjunction with sexual intercourse. One user reported that it meant “no tension for 
three months”. In Lucknow, convenience and fewer side effects emerged as the 
perceived advantages. In terms of disadvantages, amenorrhoea, increase in weight 
and spotting were some of the significant disadvantages mentioned. 
Provides protection for 3 months 
Effectiveness 
Easy to use 
Has no side effects 
Disadvantages 
Cost is not high 







52 I 73 
15 31 
Bleeding 
Lack of interest in sex 
Pain in vagina/ abdomen 





1 1  14 
n= 176 n = l l 4  
Reasons for Discontinuing DMPA 
Amenorrhoea and bleeding were the main reasons given by women for discontinuing 
use of DMPA, although about one-third mentioned multiple side effects. Other side 
effects mentioned were weakness, pain, vomiting and lack of interest in sex. Table 
15 provides a distribution of which side effects were mentioned as reasons for 
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discontinuing use. Other reasons for discontinuation cited included desire for another 
pregnancy (3 percent), and interest in a sterilization (5 percent). 
The differences between clinics in side effects mentioned is noteworthy. For 
example, 20 percent of discontinuers in Agra mention bleeding, while bleeding or 
spotting are not mentioned by all in Lucknow and by only 6 percent of women who 
discontinued use in Varanasi. Recall that nearly 80 of DMPA acceptors in Agra had 
undergone an MTP, suggesting that some side effects may also be related to other 
clinical procedures the women had been cxposed to. The importance of counseling 
cannot be over emphasized, particularly anoi ig ivomen receiving multiple services. 
Table 15 Side Effects Mentioned by Women who Discontinued DMPA Use 
Method Used after Discontinuing DMPA 
Following discontinuation of DMPA, about 6(J percent of women decided to use 
another family planning method (see Table 16). This suggests that many women 
continued to be concerned about an unwanted pregnancy and were unhappy with 
DMPA as a method choice. About one-fourth of discontinuers began to use 
condoms, and another 18 percent began taking orals. Recall that about 35 percent of 
all DMPA acceptors were interested in spacing rather than limiting births. Not all 
women returned to PSS for supplies as, for man!, inexpensive supplies of orals and 
condoms were available through outlets closer to their home. In Varanasi, a large 
proportion of users (28 percent) adopted oral pills, and in Lucknow 16 percent 
adopted sterilization. In Agra and Varanasi a large number of acceptors who 
discontinued with the method (56 and 37 percznt respectively) did not adopt any 
other method. 
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Table 16 Family Planning Method Used After Discontinuing DMPA 
Intention to Use DMPA in the Future 
As seen in Table 17. when asked how long current users planned to continue with 
DMPA, respondents in Lucknow showed more interest to continue than those at 
clinics with lower prices. In Agra and Varanasi close to one-fourth of the women 
stated that they wanted to use DMPA for less than six months, while only 2 percent 
of women in Lucknow wanted to use it for such a short period. When data on the 
intention to purchase DMPA in the future was analyzed by experience with side 
effects, those with reported side effects showed a much lower purchase intent and 
less sensitivity to price increase than those uho had experienced no side effects. 
Table 17 Length of Intended use of DMPA among Current Users 
Figure 3 illustrates the impact on price on the future intention of current users to 
purchase DMPA, as measured by client's report they would "definitely" use DMPA 
at each price. The response of users differed significantly by clinic. For example, 
while fewer users in Lucknow and Agra indicated they would "definitely" use DMPA 
as the price varied from Rs. 50 to Rs. 150. in Varanasi only about 10 percent of 
current users planned to "definitely use DMP 4" at any price. Once a product is 
provided free. it appears that a substantial increase in cost would be unacceptable. 
Recall that there was little relationship of price to actual continuation among all 
acceptors. 
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Figure 3 Price and Future Intent to Use DMPA 
IMPACT OF PRICE ON PURCHASE INTENT 
Current Users 
Rs.50 Rs.100 Rs.150 
Price Options 
Lucknow 
Vara n asi 
-- All 
Ag ra - . - .  . . . . . . . . 
D. Issues of Price and Marketing of DMPA 
There was a separate technical paper produced on the analysis of the cost of 
providing DMPA at all three PSS clinics (RamaRao et al, 1997). The analysis used 
a methodology which estimates cost based on major components of care, and the 
time spent in providing services to each individual client (AVSC, 1996; Janowitz and 
Bratt, 1994). 'The wholesale price to PSS of DMPA from Pharmacia & Upjohn was 
about Rs. 95 per dose at the outset of the study. This price is variable as the 
wholesale price for the same product is currently about Rs. 120 in the Indian market. 
DMPA is available in the public sector 'it no cost to the client in Nepal and 
Bangladesh. 
Table 18 presents a description of annual revenues and loss (or gain) based upon the 
annual costs of providing DMPA in each clinic. The cost per client was estimated 
based on the type of DMI'A services provided. Prices varied by clinic due to the 
variation in the time spent by providers on each activity and the average number of 
clients served during a month. Total revenues from DMPA sales ranged from Rs. 
13,080 in Varanasi to Rs. 29,160 in Lucknow. Despite the differences in the price 
charged for DMPA, the difference in revenue between Agra and Lucknow is not 
large, given the common fixed gynaecologicd fees charged at each site and the larger 
number of clients paying for services in Agra. 
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Table 18 Annual Revenue and Loss/Gain 












Per Client 1 Agra 1 -78 
Lucknow -5 1 
Varanasi -99 









Based on the annual costs and the income generated by the price of DMPA and 
clinical examination, an estimate of annual loss or gain from DMPA service 
provision was calculated for PSS. Estimates of advertising costs ranged frcm about 
Rs. 72,000 in Varanasi to a maximum of Its 108,000 in Agra (US$2,016 to 
US$3,025). It is clear that the costs of advertising can not be covered within the 
present pricing structure, even at the highest price of Rs. 100 per injection. However, 
if the advertising budget came from other sources, then Rs. 100 was the price at 
which clinics would be able to offer this service n ithout a loss. However, this figure 
is heavily dependent on the wholesale price of DMPA. Clearly the procurement cost 
is the most important factor when assessing the cost feasibility of providing DMPA 
to women in the urban, lower, and middle incwtre bracket. 
Table 19 provides data on the comparative costs of products in the Lucknow market 
when the cost study was conducted in Januarq 1907. Prices in the other cities varied 
little for these items. It should be noted that the median family income per month of 
acceptors interviewed in the follow-up was almut Rs. 5000 (US$140). At the price 
of Rs. 100 in Lucknow, DMPA is still relaticely expensive when compared with 
other products, such as cooking items, personal hygiene products, or clothing. It is 
even expensive compared to other contraceptives available through PSS. For 
example, orals such as Mala N and condoms such as Nirodh, government products 
which are distributed by PSS, are provided free of charge. Sterilization services are 
also provided free, and the government sanctioned user fee of Rs. 145 is paid to 
clients to cover their expenses. Many women \\rho do not work outside the home 
may also have to ask their spouses for funds to cover the transportation costs, 
examination charge and DMPA purchase price. 
But the purchase price is not the only consideration. For example, sanitary pads are 
still seen as a luxury for many urban women i n  [Ittar Pradesh. If bleeding problems 
28 
associated with DMPA use require additional sanitary protection, the effective cost 
of DMPA for the client would also increase. Likewise if the injections are only 
available at the PSS clinic, as opposed to the local pharmacist or medical practitioner, 
then the client’s transportation costs and other opportunity costs to the client should 
also be considered. 
Condoms (3 pieces) 
MTP 
Table 19 ComDarative Prices in Lucknow Jan. 1996 
5 
375-625 
ITEMS 11 PRICE Rs. 
I I) 
Sanitary Pads ( I  0) 
Pregnancy Test 
Tooth Paste (Tube) 




Cooking Oil ( 1  kg) 
Eyebrow Threading 






I Sugar ( 1  kg) I l 4  I 
Figure 4 illustrates the effect on net revenue to PSS when variations in the wholesale 
commodity prices of DMPA are assumed. At the wholesale price of Rs. 95, only 
Lucknow which charges Rs. 100 has a positive balance per 100 clients (Rs. 761). 
Were wholesale prices to be reduced to Rs. 65,1,ucknow would still have a positive 
balance, but Agra and Varanasi would still require a subsidy. If the wholesale price 
were Rs. 35 ,  then both Agra and Lucknow clinics would generate income from the 
sale of DMPA. Clearly, unless PSS receives DMPA through a donation, fiee 
distribution of the product would not be cost-effcctive. At the wholesale price of Rs. 
35, Lucknow would generate over Rs. 12,000 !or every 100 DMPA clients. While 
this would not be enough for advertisement through billboards, it might be sufficient 
to cover the cost of more interpersonal comriiunication strategies, e.g. having clients 
interested in DMPA meet satisfied users. This analysis strongly suggests that PSS 
work closely with potential suppliers to reduce the cost of the commodity before 
expanding the availability of the product fL1rthc.r. 
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Figure 4. Net Income at Different Wholesale Costs and Consumer Prices 
















There is still a great deal to be learned about the potential market for DMPA in India. 
Neither the manufacturer nor PSS is suggesting that the product should replace other 
contraceptive products alrezdy in the market. Rather the service is intended to 
expanded choices available to women, and as such it represents an important 
improvement to overall quality of care. 
Counseling is an important element of quality in this study. In every clinic PSS 
employs an office manager, who is also responsible for client intake and provides 
counseling to clients before they see a physician. When replicating these services, 
it is critical that counseling be given priority to ensure that clients have adequate 
knowledge and understanding of IIMPA and the likelihood of menstrual 
irregularities. 
Many factors other than price affect access to this product, including client 
preferences, provider experience and the density of service delivery points offering 
the service. For example, one barrier to access to DMPA in the three cities studied 
is that PSS is the only major provider of the product. Other clinic sites where DMPA 
might be provided, e.g. KGM Hospital and thc Family Planning Association of India 
clinic in Lucknow, report only a few users and no stocks on hand. Most women who 
want to use DMPA must go to the PSS clinic. rather than their local doctor or 
pharmacist. to obtain the service. 
An important issue to remember is that PSS is already providing DMPA services in 
all its thirty clinics. PSS has been providing IIMPA in its clinics since 1994. As of 
October 1997. all clinics are providing the product at Rs. 50, the price charged at the 
Agra site. This is a major change since prior to the study all clinics were charging 
Rs. 150 for the same product. The cost study identified that at this price, while the 
services would have to be subsidized, the actual c ost to PSS of providing this service 
would be relatively modest given the numbcr oi’clients. The critical issue for PSS 
to expand the service at this price, liowcve~. would be to ensure the supply of the 
commodity at a cost of around Rs. 35. 
Not to be overlooked is that fact that the needs of an important segment of clients, 
i.e. younger and lower parity women interested in spacing, are being met by this 
service. Moreover, they are willing to pay for the entire costs of the product and the 
service, as evidenced in the PSS clinic in Lucknow. Several questions remain, 
however. What would the acceptability of the product be to clients of another 
source? Given the large number of MTP clients served by PSS, would another 
provider offer an alternative for a larger number of clients? What is the role of 
Pharmacia & Upjohn in providing national marketing support to the product? And 
finally, what is the interest of the public sec1or in  DMPA as part of its commitment 
to expanding contraception choices for couples 
111. CONCLUSION 
The results document that the DMPA serviccs and counseling provided by PSS were 
of good quality. Initial use of the product seems to be sensitive to price in the context 
of Uttar Pradesh, while continuation is determined by a combination of factors, of 
which pzrsonal experience with the product is most important. In PSS’s experience 
the role of the physician supplements that 93f the counselor for new clients. 
Continuing clients with amenorrhoea, howevel, want to be reassured that they are 
indeed not pregnant, and value contact with a physician. 
The low key advertising of the services secnied to have little immediate effect on 
DMPA use, but at the same time there was no adverse response to the publicity. At 
the PSS clinics, about half of the users adopt DMPA following an MTP. The total 
number of clients served and doses prolideti IS  relatively modest in absolute terms, 
but significant relative to overall sales o t’ the product in Uttar Pradesh, and segment 
of young, low parity PSS clients served. Thc  ic sts of providing the service for PSS 
appear affordable at the moment, with the cost of commodities being the most critical 
element to be resolved prior to further investment in expansion. 
In conclusion, DMPA appears to be an acceptable, safe method of contraception 
when offered in a context of good client counseling and follow-up. By providing 
DMPA, PSS offered a broader contraceptiix choice to their clients. More effective 
public information about the method and its availability would greater improve its 
access. Ensuring the availability of the product at an affordable wholesale price in 
India would both meet the needs ofpotential clients as well as facilitate the financial 
sustainability of the service by PSS. 
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